Evidence map›Paper›PMID 41296255›Full record

ArticleCurrent medical science2025

LncRNA C9orf139 Promotes Acute Myeloid Leukemia Cell Proliferation by Sponging miR-24-3p to Upregulate TAOK1.

Wei Qin, Mei-Yu Chen, Xiao-Hui Cai, Ping Chen, Rui-Yi Zhang, Xu-Zhang Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei Qin *Department of Hematology, The Third Affiliated Hospital of Nanjing Medical University & Changzhou Medical Center, The Second People's Hospital of Changzhou, Changzhou, 213000, China.
Mei-Yu Chen *Department of Hematology, The Third Affiliated Hospital of Nanjing Medical University & Changzhou Medical Center, The Second People's Hospital of Changzhou, Changzhou, 213000, China.
Xiao-Hui CaiDepartment of Hematology, The Third Affiliated Hospital of Nanjing Medical University & Changzhou Medical Center, The Second People's Hospital of Changzhou, Changzhou, 213000, China.
Ping ChenSuzhou Jsuniwell Medical Laboratory, Suzhou, 215000, China.
Rui-Yi ZhangSuzhou Jsuniwell Medical Laboratory, Suzhou, 215000, China.
Xu-Zhang LuDepartment of Hematology, The Third Affiliated Hospital of Nanjing Medical University & Changzhou Medical Center, The Second People's Hospital of Changzhou, Changzhou, 213000, China. luxuzhang2023@njmu.edu.cn.

Funding

Education Research Project of Nanjing Medical University 2023ZC086the Youth Talent Science and Technology Project of Health Commission of Changzhou QN202223
6 · The paper itself

Abstract

objectiveLong non-coding RNAs (lncRNAs) are critical in the pathogenesis of hematological malignancies, including acute myeloid leukemia (AML). However, the specific role and underlying mechanisms of the lncRNA chromosome 9 open reading frame 139 (C9orf139) in AML remain unclear. This study aimed to investigate the role and molecular mechanism of C9orf139 in AML development.

methodsAML-related sequencing and microarray data were retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Significant lncRNAs and mRNAs influencing AML progression were identified and analyzed. A competing endogenous RNA network involving lncRNA-microRNA (miRNA)3-mRNA interactions was subsequently constructed. The expression levels of C9orf139, miR-24-3p, and human TAO kinase 1 (TAOK1) were assessed via real-time fluorescent quantitative polymerase chain reaction (PCR). Cell proliferation was evaluated via the Cell Counting Kit-8 (CCK8) assay, whereas Transwell assays were used to assess cell invasion and migration. Apoptosis was measured by Annexin V Fluorescein Isothiocyanate (FITC) double staining. Tumor formation in nude mice was assessed to examine the effect of C9orf139 on in vivo tumor growth. The C9orf139-miR-24-3p-TAOK1 regulatory axis was validated via dual luciferase reporter assays and RNA-binding protein immunoprecipitation (RIP). Western blot assays were used to assess the expression and phosphorylation of key proteins in the mitogen-activated protein kinase (MAPK) signaling pathway.

resultsBioinformatics analysis identified C9orf139 and TAOK1 as differentially expressed genes that play key roles in AML pathogenesis. The C9orf139-miR-24-3p-TAOK1 axis was tightly linked to AML development, as confirmed by clinical sample analysis. In vitro, C9orf139 downregulation resulted in reduced proliferation, invasion, and migration and enhanced the apoptosis of AML cells. In vivo, the inhibition of C9orf139 significantly impaired tumor growth in nude mice. The regulatory axis was further validated. C9orf139 knockdown reduced the phosphorylation levels of the key MAPK pathway proteins, including Raf, mitogen-activated protein kinase kinase (MEK), and extracellular regulated protein kinase (ERK).

conclusionC9orf139 regulates AML progression by activating the MAPK signaling pathway through the C9orf139-miR-24-3p-TAOK1 axis.

Indexed as

Leukemia, Myeloid, AcuteMicroRNAsProtein Serine-Threonine KinasesRNA, Long NoncodingAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudeUp-RegulationMicroRNAsMIRN24 microRNA, humanProtein Serine-Threonine KinasesRNA, Long NoncodingAcute myeloid leukemiaC9orf139Differentiation; CeRNA; MARK signaling pathwayMiR-24-3pProliferationTAOK1

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.